Pucotenlimab
Sponsors
Sun Yat-sen University, Second Affiliated Hospital, School of Medicine, Zhejiang University, Sir Run Run Shaw Hospital, Groupe Oncologie Radiotherapie Tete et Cou, Zhejiang Provincial People's Hospital
Conditions
Colorectal Cancer (CRC)Cutaneous Squamous Cell Carcinoma (CSCC)Hepatic Arterial Infusion ChemotherapyIntrahepatic Cholangiocarcinoma (Icc)LDRTLocally Advanced Head and Neck Squamous Cell CarcinomaPD-1 InhibitorPD-L1
Phase 1
Effectiveness of Pucotenlimab Combined With Standard Chemotherapy Regimen
RecruitingNCT06456892
Start: 2024-06-06End: 2026-12-06Target: 82Updated: 2024-06-13
LDRT Combined With Pucotenlimab and Standard Therapy for Advanced Pancreatic Cancer: A Single-Arm Study
RecruitingNCT07312422
Start: 2025-09-30End: 2026-10-30Target: 10Updated: 2026-01-26
Phase 2
Pucotenlimab Plus Radiotherapy and Chemotherapy for Neoadjuvant Treatment of Locally Advanced Rectal Cance(PUCRT)
RecruitingNCT06770270
Start: 2024-08-01End: 2030-06-30Target: 68Updated: 2025-09-04
Short-Course Radiotherapy Combined with Intracavitary Brachytherapy Followed by Pucotenlimab, Bevacizumab, Oxaliplatin, and Trifluridine/Tipiracil (TAS-102) for Total Neoadjuvant Therapy of Microsatellite Stable (MSS) Locally Advanced Low Rectal Cancer
Not yet recruitingNCT06872606
Start: 2025-04-01End: 2028-04-01Target: 33Updated: 2025-03-12
The Efficacy and Safety of Pucotenlimab Combined With TP Chemotherapy as Neoadjuvant Therapy for Locally Advanced HNSCC
Not yet recruitingNCT06895369
Start: 2025-05-01End: 2033-12-31Target: 30Updated: 2025-03-26
Clinical Trial Comparing Induction Treatment With EGFR-ADC MRG003 Alone or in Combination With the Anti PD1 Pucotenlimab, Followed by Radiochemotherapy in Locally Advanced Squamous Cell Cancers of the Head and Neck
Not yet recruitingNCT06959108
Start: 2025-10-31End: 2029-10-31Target: 106Updated: 2025-09-02
FOLFOX-HAIC Combined With Donafenib and Pucotenlimab as First-Line Treatment for Unresectable Intrahepatic Cholangiocarcinoma
Not yet recruitingNCT07353827
Start: 2026-02-01End: 2028-12-31Target: 36Updated: 2026-01-20
Pucotenlimab Combined With Becotatug Vedotin in Advanced Cutaneous Squamous Cell Carcinoma
Not yet recruitingNCT07394244
Start: 2026-01-09End: 2028-12-31Target: 38Updated: 2026-02-06
Low-Dose Radiotherapy to Sensitize Pucotenlimab Plus CAPEOX for pMMR Locally Advanced Rectal Cancer
RecruitingNCT07448142
Start: 2026-03-15End: 2032-09-01Target: 50Updated: 2026-03-04
The Safety and Efficacy of MRG003 With or Without Putrelimab in Recurrent or Metastatic Salivary Gland Cancer: a Single-center, Open-label Cohort Study
RecruitingNCT07464366
Start: 2026-03-19End: 2029-09-30Target: 90Updated: 2026-04-01